Loading...
•
Mar 31, 2025
Mimedx Q1 2025 Earnings Report
Reported Q1 2025 operating and financial results
Key Takeaways
MIMEDX delivered a solid first quarter for 2025 with 4% year-over-year net sales growth driven by strong performance in surgical products. While facing setbacks with LCDs, the company is strategically adding new products to navigate the reimbursement landscape and remains focused on expanding the use cases for its proprietary technology.
Net sales for Q1 2025 were $88 million, a 4% increase compared to the prior year.
Surgical products experienced significant growth of 16% in the first quarter.
GAAP Net Income and Earnings Per Share for Q1 were $7 million and $0.05, respectively.
Adjusted EBITDA for the first quarter was $17.2 million, representing a margin of 19.5%.
Revenue by Segment
Forward Guidance
MIMEDX expects net sales growth for 2025 to be at least in the high single-digits and anticipates a full-year Adjusted EBITDA margin above 20%. The company is focused on expanding use cases for its technology and introducing new products.
Positive Outlook
- Expects net sales growth for 2025 to be at least in the high single-digits.
- Anticipates full-year Adjusted EBITDA margin to be above 20%.
- Longer-term goal of annual net sales growth in the low double-digits.
- Longer-term goal of an adjusted EBITDA margin above 20%.
- Plan to introduce additional products throughout the year.
Challenges Ahead
- Further delay to the LCDs is a disappointing setback.
- Future sales are uncertain and affected by competition, access to customers, patient access, and reimbursement.
- Company may change plans due to unforeseen circumstances.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...